Osteopontin: A Bone-Derived Protein Involved in Rheumatoid Arthritis and Osteoarthritis Immunopathology.

Osteopontin (OPN) is a bone-derived phosphoglycoprotein related to physiological and pathological mechanisms that nowadays has gained relevance due to its role in the immune system response to chronic degenerative diseases, including rheumatoid arthritis (RA) and osteoarthritis (OA). OPN is an extracellular matrix (ECM) glycoprotein that plays a critical role in bone remodeling. Therefore, it is an effector molecule that promotes joint and cartilage destruction observed in clinical studies, in vitro assays, and animal models of RA and OA. Since OPN undergoes multiple modifications, including posttranslational changes, proteolytic cleavage, and binding to a wide range of receptors, the mechanisms by which it produces its effects, in some cases, remain unclear. Although there is strong evidence that OPN contributes significantly to the immunopathology of RA and OA when considering it as a common denominator molecule, some experimental trial results argue for its protective role in rheumatic diseases. Elucidating in detail OPN involvement in bone and cartilage degeneration is of interest to the field of rheumatology. This review aims to provide evidence of the OPN's multifaceted role in promoting joint and cartilage destruction and propose it as a common denominator of AR and OA immunopathology.

Subjective well-being's alterations as risk factors for major depressive disorder during the perimenopause onset: an analytical cross-sectional study amongst Mexican women residing in Guadalajara, Jalisco.

BACKGROUND: Subjective well-being (SWB) can be defined as a self-report evaluation that reflects the satisfaction, and emotional level, over several social and personal indicators. Alterations in these indicators could become risk factors (RF) for major depressive disorder (MDD), but this association has not been studied at women's life stages such as the perimenopause onset, despite its increasing prevalence for depressive symptomatology. Therefore, the aim of this study was to identify if SWB's alterations determine RF for MDD during the perimenopause. METHODS: An analytical cross-sectional study was realized in 252 Mexican women with perimenopause's age range (48 ± 1.7) and menopausal symptomatology, treated on Medical Units belonging to Jalisco's 13th Health-Region. We applied the INEGI's Basic Self-Reported Wellbeing Survey (BIARE) that measured 30 SWB's indicators. To identify MDD's presence, the Beck's Depression Inventory-II (BDI-II) was applied. The sample was studied with associative analysis, along with logistic regression models, to determine adjusted odds ratio (aOR) and corresponding 95% confidence interval (95% CI). RESULTS: Trough the BDI-II we identified 40.5% women with MDD. When compared with the undepressed group we found lower scores in all the SWB's indicators, along with significant associations for depressive symptomatology. However, the logistic regression allowed us to identify significant RF when the women specifically reported personal life-dissatisfaction (aOR 9.6, 95% CI 1.90-17.68), emotional imbalances between happiness/sadness (aOR 7.1, 95% CI 1.49-13.57) and concentration/boredom (aOR 6.7, 95% CI 1.43-13.48); free-time dissatisfaction (aOR 5.5, 95% CI 1.17-5.70), public security unconformity (aOR 5.4, 95% CI 2.20-11.3), and sense of purposelessness (aOR 4.2, 95% CI 1.07-19.41). CONCLUSION: The main objective of the study was to determine if SWB's alterations are RF for depressive symptomatology, finding that social indicators with low scores are associated with MDD by means of aOR -Which were higher when compared to international research studies. Considering this, we suggest that more studies should be implemented, in order to understand and correctly attend the women's social conditions during their perimenopause transition.

The Newcastle satisfaction with nursing scales in a Mexican Oncology Hospital.

OBJECTIVES: The principal aim of this study was to identify whether the Newcastle Satisfaction with Nursing Scales (NSNS) could be used on cancer patients. METHODS: This was a descriptive, cross-sectional study carried out on cancer patients (n = 298). RESULTS: We found that a majority of cancer patients were around 50 years old (hospitalized patients [HP]: 49.5 ± 14.9; chemotherapy outpatients [COP]: 49.4 ± 12.7), were female (HP: 74%; COP: 63.5%), and had received education at least up to elementary level (HP: 70%; COP: 80%). Breast cancer was the principal type of cancer (>34%) in both groups (HP and COP). The groups were comparable in age, sex distribution, place of origin, educational qualification, and type of cancer. Among HP, the experience and satisfaction scales of the NSNS showed good internal consistency (n = 235, α >0.9, r > 0.7), while among COP, only the satisfaction scale showed good internal consistency (n = 62, α = 1.00). Most patients' perceptions (level of satisfaction) of hospitalization and chemotherapy services were positive (98% and 97%, respectively). CONCLUSION: An NSNS instrument specifically designed for ambulatory care cancer patients is necessary for it to be useful in assessing cancer patients' perception of nursing care. This will help improve the quality of care in Mexico.The presence of cancer by itself could modify the patients' satisfaction level. Further large-scale studies are required to investigate the patients' perceptions of nursing care using the NSNS on different cancer patient groups.

Contribution of rs3211938 polymorphism at CD36 to glucose levels, oxidized low-density lipoproteins, insulin resistance, and body mass index in Mexican mestizos with type-2 diabetes from western Mexico.

INTRODUCTION: Background: type-2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance (IR), and abnormal fatty acid metabolism in which the CD36 receptor has been implicated in glucose and lipid dysregulation. Objective: to evaluate the contribution of polymorphism CD36 rs3211938 to metabolic profile in T2DM Mexican mestizos from western Mexico. Methods: we included 115 individuals classified as non-T2DM (NT2DM) adults and T2DM patients. Polymorphism CD36 rs3211938 was assessed by PCR-RFLP. Anthropometric and metabolic markers were measured by routine methods, and insulin and oxidized LDL (ox-LDL) were measured by ELISA. Results: the distribution of genotypes between NT2DM and T2DM patients was different (p < 0.001), as was the allele frequency (p = 0.002). NT2DM TG carriers showed the lowest levels of basal insulin and HOMA-IR index in comparison with TT carriers (p < 0.05 and p < 0.05, respectively). In the T2DM group TG carriers showed high BMI, WHR, and weight values (p = 0.001; p ≤ 0.05 and p < 0.05, respectively), and the highest levels of basal glucose, HDL-cholesterol, ox-LDL, and HOMA-IR (p < 0.001; p < 0.001; p < 0.001, and p = 0.001, respectively) in comparison with diabetic TT carriers. Conclusion: the CD36 rs3211938 TG genotype is associated with high levels of glucose, ox-LDL, HDL-cholesterol, and IR, and with increased BMI in Mexican mestizo T2DM patients from western Mexico.

INTRODUCCIÓN: Antecedentes: la diabetes mellitus de tipo 2 (DMT2) es un trastorno metabólico crónico caracterizado por hiperglucemia, resistencia a la insulina (RI) y metabolismo anormal de ácidos grasos en el que se ha implicado el receptor CD36 en la disregulación de la glucosa y los lípidos. Objetivo: evaluar la contribución del polimorfismo CD36 rs3211938 al perfil metabólico en individuos mestizos mexicanos con DMT2 del occidente de México. Métodos: se incluyeron 115 individuos clasificados en adultos sin DMT2 (NDMT2) y pacientes con DMT2. El polimorfismo CD36 rs3211938 se identificó mediante PCR-RFLP. Las mediciones antropométricas y metabólicas se realizaron mediante métodos de rutina y la insulina y las LDL-oxidadas (LDL-ox) se midieron por ELISA. Resultados: las distribuciones de los genotipos entre los pacientes NDMT2 y DMT2 fueron diferentes (p < 0,001), así como la frecuencia alélica (p = 0,002). Los individuos NDMT2 portadores del genotipo TG mostraron niveles más bajos de insulina basal e índice HOMA-IR en comparación con los portadores del genotipo TT (p < 0,05 y p < 0,05, respectivamente). En el grupo DMT2, los portadores del genotipo TG presentaron valores elevados de índice de masa corporal (IMC), índice cintura-cadera (ICC) y peso (p = 0,001; p < 0,05 y p < 0,05, respectivamente) y niveles más altos de glucosa basal, HDL-colesterol, LDL-ox y HOMA-IR (p < 0,001; p < 0,001; p < 0,001 y p = 0,001, respectivamente) en comparación con los portadores del genotipo TT. Conclusión: el genotipo TG del polimorfismo CD36 rs3211938 se asocia a altos niveles de glucosa, ox-LDL, HDL-colesterol y RI, y a aumentos del IMC en los pacientes mestizos mexicanos con DMT2 del occidente de México.

PTPN22 gene functional polymorphism (rs2476601) in older adults with frailty syndrome.

The frailty syndrome is a common clinical marker of vulnerability in older adults conducive to an overall decline in inflammatory stress responsiveness; yet little is known about the genetic risk factors for frailty in elderly. Our aim was to investigate the association between the rs2476601 polymorphism in PTPN22 gene and susceptibility to frailty in Mexican older adults. Data included 630 subjects 70 and older from The Coyoacán cohort, classified as frail, pre-frail, and non-frail following Fried's criteria. Sociodemographic and clinical characteristics were compared between groups at baseline and after a multivariate analysis. The rs2476601 polymorphism was genotyped by TaqMan genotyping assay using real-time PCR and genotype frequencies were determined for each frailty phenotype in all participants and subsets by age range. Genetic association was examined using stratified and interaction analyses adjusting for age, sex and variables selected in the multivariate analysis. Disability for day-life activities, depression and cognitive impairment were associated with the risk of pre-frailty and frailty at baseline and after adjustment. Carrying the T allele increased significantly the risk of frailty in patients 76 and older (OR 5.64, 95% CI 4.112-7.165) and decreased the risk of pre-frailty under no clinical signs of depression (OR 0.53; 95% CI 0.17-1.71). The PTPN22 polymorphism, rs2476601, could be a genetic risk factor for frailty as subject to quality of life. This is the first study analyzing such relationship in Mexican older adults. Confirming these findings requires additional association studies on wider age ranges in populations of older adults with frailty syndrome.

Genetic biomarkers related to hemarthrosis, inflammation, and cartilage structure in pediatric patients with hemophilic arthropathy.

BACKGROUND: The pathophysiology of hemophilic arthropathy is complex and not completely understood. In this study, we aimed to identify biomarkers that can affect the hemophilic arthropathy severity. METHODS: Fifty patients were analyzed for biomarker frequencies; in 37 patients, articular symptoms were evaluated based on the physical joint examination score, and in 18, it was based on magnetic resonance imaging. Eight polymorphisms, namely FV 1691G>A, FII 20210G>A, MTHFR 677C>T and 1298A>C, TNFα-308G>A and -238G>A, ACAN VNTR, and IL1RN*2-VNTR were identified. RESULTS: Patients with the MTHFR 677TT genotype showed a higher number of affected joints (1.83 ± 0.9 vs. 0.55 ± 0.7 for CC; p = .023), whereas those with the MTHFR 1298AC genotype exhibited higher effusion according to two radiologists (0.90 ± 0.31/1.20 ± 0.63 vs. 0.38 ± 0.52/0.50 ± 0.53 for AA genotype; p = .043/0.036, respectively). In addition, patients with the TNFα-308GA genotype had more subchondral cysts (0.75 ± 0.95 vs. 0.07 ± 0.26 for GG genotype; p = .041). CONCLUSIONS: The distribution of risk genotypes for MTHFR and TNFα-308GA suggests their association with clinical parameters of hemophilic arthropathy. Cohort studies are essential to verify these associations.

Riesgo para el desarrollo de trastorno depresivo mayor al existir alteraciones en la sintomatología menopaúsica en mujeres de Guadalajara, Jalisco / Risk for the development of major depressive disorder when there are alterations in menopausal symptoms in women from Guadalajara, Jalisco

RESUMEN Antecedentes: El Trastorno Depresivo Mayor (TDM) puede presentarse durante el inicio de la menopausia, variando su prevalencia de acuerdo a diferentes factores de riesgo clínicos y sociodemográficos; presentándose una mayor asociación al existir alteraciones en la sintomatología menopaúsica. Ante esto, se buscará determinar el riesgo para desarrollar TDM al presentar alteraciones en la sintomatología menopaúsica. Metodología: Es un diseño transversal analítico que incluyó a 252 mujeres iniciando su menopausia (48±1.7 años), atendidas en centros de salud de Guadalajara, Jalisco. Las variables analizadas fueron antecedentes sociodemográficos, utilizando el Inventario de Depresión de Beck para identificar el TDM y la Escala de Valoración de la Menopausia para determinar alteraciones en los principales dominios sintomatológicos de la menopausia. Se realizaron análisis descriptivos y de asociación por medio de Odds Ratio (OR), aplicando finalmente una regresión logística. Resultados: La prevalencia de TDM fue de 40.5%, teniendo asociación con el antecedente de uso de anticonceptivos y con el agravamiento en la sintomatología menopaúsica. El análisis ajustado determinó que hay más riesgo de presentar TDM cuando existen alteraciones en los dominios sintomatológicos, tales como en el somático (OR 3.96, IC95% 1.58-9.95), el urogenital (OR 4.29, IC95% 2.13-8.65) y el psicológico (OR 13.55, IC95% 3.97-46.30). Conclusión: La presencia de alteraciones en la sintomatología menopaúsica se encuentra asociado con un mayor riesgo de presentar TDM, sobre todo si el dominio psicológico está afectado, por lo cual es necesario que el personal de salud identifique estas alteraciones y brinde un manejo temprano en esta etapa de la vida.

ABSTRACT Background: Major Depressive Disorder (MDD) can occur during the onset of the menopause, varying its prevalence according to different clinical and sociodemographic risk factors; presenting a greater association with the existence of alterations in the menopausal symptomatology. Given this, we will seek to determine the risk to develop MDD by presenting alterations in the menopausal symptoms Methodology: It is an analytical cross-sectional design that included 252 women beginning their menopause (48±1.7 years old), and who were attended in health centers of Guadalajara, Jalisco. The analyzed variables were their sociodemographic background, using the Beck Depression Inventory to identify the MDD and the Menopause Rating Scale to determine alterations in the main symptomatological domains of the menopause. Descriptive and association analyzes were performed by means of Odds Ratio (OR), subsequently applying a logistic regression model. Results: The prevalence of MDD was 40.5%, with significant associations with the history of contraceptive use and the worsening of menopausal symptoms. The adjusted analysis allowed us to determine that there is more risk for developing MDD when there were alterations in the symptomatological domains, such as in the somatic (OR 3.96, 95% CI 1.58-9.95), the urogenital (OR 4.29, IC95% 2.13-8.65) and in the psychological (OR 13.55, IC95% 3.97-46.30). Conclusion: The presence of alterations in the menopausal symptomatology is associated with an increased risk of developing MDD, especially if the psychological domain is affected, which is why it is necessary for health personnel to identify these alterations and provide early management in this stage of live.